Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
Optum, Eden Prairie, MN, USA.
Curr Med Res Opin. 2019 Jan;35(1):63-71. doi: 10.1080/03007995.2018.1519499. Epub 2018 Sep 15.
Evaluation of provider compliance with antiretroviral (ARV) treatment guidelines and patient adherence to ARVs is important for HIV care quality assessment; however, there are few current real-world data for guideline compliance and ARV adherence in the US. This study evaluated provider compliance with US Department of Health and Human Services (DHHS) guidelines and patient adherence to ARVs in a US population of patients with HIV. This was a retrospective claims study of adults with HIV-1 receiving ARV treatment between January 2010-December 2014. Follow-up began at first ARV treatment and ended at health plan disenrollment or study end. ARV regimens for treatment-naïve patients were categorized as "preferred/recommended", "alternative", or "non-preferred/recommended/alternative" according to DHHS guidelines. ARV adherence was evaluated using proportion of days covered (PDC) and medication possession ratio (MPR). The analysis included 25,320 patients (84.4% male, mean age 45.3 years) and 39,071 regimens. Preferred/recommended regimens were most common during each study year, but the proportion of non-preferred/recommended/alternative regimens was substantial (15.9-20.6%). Only 53.6% of patients had optimal adherence by PDC ≥0.95, and 57.9% by MPR ≥0.95. Guideline non-compliance and sub-optimal adherence were more prevalent among female vs male patients (22.6% vs 14.8% [in 2014] and 65.9% vs 53.7%, respectively). Provider non-compliance with DHHS guidelines and sub-optimal ARV adherence among patients with HIV remain common in real-world practice, particularly for female patients. Healthcare providers should follow the latest clinical guidelines to ensure that patients receive recommended therapy, and address non-adherence when selecting ARV regimens.
评估医疗服务提供者(provider)遵守抗逆转录病毒(ARV)治疗指南和患者对 ARV 的依从性(adherence)对于 HIV 护理质量评估至关重要;然而,目前美国关于指南遵守情况和 ARV 依从性的实际数据很少。本研究评估了美国 HIV 患者人群中医疗服务提供者遵守美国卫生与公众服务部(DHHS)指南的情况以及患者对 ARV 的依从性。这是一项回顾性的理赔研究,纳入了 2010 年 1 月至 2014 年 12 月期间接受 ARV 治疗的成人 HIV-1 患者。随访从首次 ARV 治疗开始,到健康计划退出或研究结束结束。根据 DHHS 指南,将初治患者的 ARV 方案分为“首选/推荐”、“替代”或“非首选/推荐/替代”。采用比例覆盖天数(PDC)和药物维持率(MPR)评估 ARV 依从性。该分析共纳入 25320 例患者(84.4%为男性,平均年龄 45.3 岁)和 39071 种方案。各研究年度首选/推荐方案最常见,但非首选/推荐/替代方案的比例相当大(15.9-20.6%)。仅有 53.6%的患者通过 PDC≥0.95 达到了最佳依从性,57.9%的患者通过 MPR≥0.95 达到了最佳依从性。女性患者的指南不遵守和依从性差的情况比男性患者更为常见(2014 年分别为 22.6%和 14.8%,以及 65.9%和 53.7%)。在现实实践中,医疗服务提供者不遵守 DHHS 指南和患者接受 HIV 治疗时依从性差的情况仍然很常见,尤其是女性患者。医疗保健提供者应遵循最新的临床指南,确保患者接受推荐的治疗,并在选择 ARV 方案时解决不依从的问题。